An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor

Vaccine

Volumn 28, Issue 41, 2010, Pages 6740-6748

  Baillie, Les W ^a,b   Huwar, Theresa B ^b   Moore, Stephen ^b   Mellado Sanchez, Gabriela ^c   Rodriguez, Liliana ^c   Neeson, Brendan N ^d   Flick Smith, Helen C ^d   Jenner, Dominic C ^d   Atkins, Helen S ^d   Ingram, Rebecca J ^e   Altmann, Danny M ^e   Nataro, James P ^c   Pasetti, Marcela F ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

^d DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anthrax; B. anthracis; Fusion protein; Lethal factor; Protection; Protective antigen; T cell; Vaccine

Indexed keywords

ANTHRAX VACCINE; BACILLUS ANTHRACIS PROTECTIVE ANTIGEN; HYBRID PROTEIN; LFD1 PAD4 FUSION PROTEIN; PROTEIN LF7; PROTEIN LFD1; PROTEIN LFD2; PROTEIN LFD3; PROTEIN LFD4; PROTEIN PAD4; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFECTION PREVENTION; LETHAL GENE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TREATMENT OUTCOME;

ANIMALS; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 77956482894     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.075     Document Type: Article

References (47)

1. Baillie L.W. Is new always better than old?: the development of human vaccines for anthrax. Hum Vaccine 2009, 5(12):806-816.
2. Knight J. Bioweapons: delivering death in the mail. Nature 2001, 414:837-838.
3. Baillie L., Read T.D. Bacillus anthracis, a bug with attitude!. Curr Opin Microbiol 2001, 4(1):78-81.
4. Pannifer A.D., Wong T.Y., Schwarzenbacher R., Renatus M., Petosa C., Bienkowska J., et al. Crystal structure of the anthrax lethal factor. Nature 2001, 414(6860):229-233.
5. Mock M., Fouet A. Anthrax. Annu Rev Microbiol 2001, 55:647-671.
6. Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., Liddington R.C. Crystal structure of the anthrax toxin protective antigen. Nature 1997, 385:833-838.
7. Hammamieh R., Ribot W.J., Abshire T.G., Jett M., Ezzell J. Activity of the Bacillus anthracis 20kDa protective antigen component. BMC Infect Dis 2008, 8:124.
8. Reason D., Liberato J., Sun J., Keitel W., Zhou J. Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infect Immun 2009, 77(5):2030-2035.
9. Reason D.C., Ullal A., Liberato J., Sun J., Keitel W., Zhou J. Domain specificity of the human antibody response to Bacillus anthracis protective antigen. Vaccine 2008, 26(32):4041-4047.
10. Flick-Smith H.C., Walker N.J., Gibson P., Bullifent H., Hayward S., Miller J., et al. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun 2002, 70(3):1653-1656.
11. Baillie L., Hebdon R., Flick-Smith H., Williamson D. Characterisation of the immune response to the UK human anthrax vaccine. FEMS Immunol Med Microbiol 2003, 36(1-2):83-86.
12. Baillie L., Townend T., Walker N., Eriksson U., Williamson D. Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol Med Microbiol 2004, 42(2):267-270.
13. Baillie L.W.J., Rodriguez A.L., Moore S., Atkins H.S., Feng C., Nataro J.P., et al. Towards a human oral vaccine for anthrax: the utility of a Salmonella typhi Ty21a-based prime-boost immunization strategy. Vaccine 2008, 26(48):6083-6091.
14. Wasserman G.M., Grabenstein J.D., Pittman P.R., Rubertone M.V., Gibbs P.P., Wang L.Z., et al. Analysis of adverse events after anthrax immunization in US army medical personnel. J Occup Environ Med 2003, 45(3):222-233.
15. Beedham R.J., Turnbull P.C., Williamson E.D. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 2001, 19(31):4409-4416.
16. Henderson D.W., Peacock S., Belton F.C. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 1956, 54(1):28-36.
17. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L.M., Norris S.L.W., Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 2004, 22(3-4):422-430.
18. Pittman P.R., Leitman S.F., Oro J.G.B., Norris S.L., Marano N.M., Ranadive M.V., et al. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin Diagn Lab Immunol 2005, 12(6):713-721.
19. Quinn C.P., Dull P.M., Semenova V., Li H., Crotty S., Taylor T.H., et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 2004, 190(7):1228-1236.
20. Galloway D., Liner A., Legutki J., Mateczun A., Barnewall R., Estep J. Genetic immunization against anthrax. Vaccine 2004, 22(13-14):1604-1608.
21. Hermanson G., Whitlow V., Parker S., Tonsky K., Rusalov D., Ferrari M., et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. PNAS 2004, 101(37):13601-13606.
22. Brenneman K, Dognanay M, Akmal A, Goldman S, Galloway D, Mateczun A. The early humoral immune response to Bacillus anthracis, in preparation.
23. Hepburn M.J., Hugh Dyson E., Simpson A.J., Brenneman K.E., Bailey N., Wilkinson L., et al. Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine. Vaccine 2007, 25(32):6089-6097.
24. Pomerantsev A.P., Staritsin N.A., Mockov Y.V., Marinin L.I. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 1997, 15(17-18):1846-1850.
25. Rosovitz M.J., Schuck P., Varughese M., Chopra A.P., Mehra V., Singh Y., et al. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem 2003, 278(33):30936-30944.
26. Hoffmaster A.R., Ravel J., Rasko D.A., Chapman G.D., Chute M.D., Marston C.K., et al. Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. PNAS 2004, 101(22):8449-8454.
27. Pezard C., Weber M., Sirard J.C., Berche P., Mock M. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immun 1995, 63(4):1369-1372.
28. Price B.M., Liner A.L., Park S., Leppla S.H., Mateczun A., Galloway D.R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 2001, 69(7):4509-4515.
29. Ballard J.D., Doling A.M., Beauregard K., Collier R.J., Starnbach M.N. Anthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T-lymphocyte epitope from ovalbumin. Infect Immun 1998, 66(2):615-619.
30. Lu Y., Friedman R., Kushner N., Doling A., Thomas L., Touzjian N., et al. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. PNAS 2000, 97(14):8027-8032.
31. Allen J.S., Skowera A., Rubin G.J., Wessely S., Peakman M. Long-lasting T cell responses to biological warfare vaccines in human vaccinees. Clin Infect Dis 2006, 43(1):1-7.
32. Laird M.W., Zukauskas D., Johnson K., Sampey G.C., Olsen H., Garcia A., et al. Production and purification of Bacillus anthracis protective antigen from Escherichia coli. Protein Expr Purif 2004, 38(1):145-152.
33. Williamson E.D., Flick-Smith H.C., LeButt C., Rowland C.A., Jones S.M., Waters E.L., et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 2005, 73(6):3598-3608.
34. Stokes M.G., Titball R.W., Neeson B.N., Galen J.E., Walker N.J., Stagg A.J., et al. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immun 2007, 75(4):1827-1834.
35. Li H., Soroka S.D., Taylor T.H., Stamey K.L., Stinson K.W., Freeman A.E., et al. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods 2008, 333(1-2):89-106.
36. Taylor T., Quinn C., Schmidt D., Freeman A., Li H., Semenova V., et al. Novel mathematical approach to TNA endpoints. 5th International Conference on Anthrax 2003.
37. Lim N.-K., Kim J.-H., Oh M.S., Lee S., Kim S.-Y., Kim K.-S., et al. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect Immun 2005, 73(10):6547-6551.
38. Albrecht M.T., Li H., Williamson E.D., LeButt C.S., Flick-Smith H.C., Quinn C.P., et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 2007, 75(11):5425-5433.
39. Nguyen M.L., Crowe S.R., Kurella S., Teryzan S., Cao B., Ballard J.D., et al. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect Immun 2009, 77(1):162-169.
40. Ballard J.D., Collier R.J., Starnbach M.N. Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo. PNAS 1996, 93(22):12531-12534.
41. McHeyzer-Williams L.J., Pelletier N., Mark L., Fazilleau N., McHeyzer-Williams M.G. Follicular helper T cells as cognate regulators of B cell immunity. Curr Opin Immunol 2009, 21(3):266-273.
42. Baillie L., Townend T., Walker N., Eriksson U., Williamson D. Characterization of the human immune response to the uk anthrax vaccine. FEMS Immunol Med Microbiol 2004, 42(2):267-270.
43. Zhao P., Liang X., Kalbfleisch J., Koo H.M., Cao B. Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum Antibodies 2003, 12(4):129-135.
44. Gentile F., Conte M., Formisano S. Thyroglobulin as an autoantigen: what can we learn about immunopathogenicity from the correlation of antigenic properties with protein structure?. Immunology 2004, 112(1):13-25.
45. Sabhnani L., Manocha M., Sridevi K., Shashikiran D., Rayanade R., Rao D.N. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles. FEMS Immunol Med Microbiol 2003, 38(3):215-229.
46. Sette A., Fleri W., Peters B., Sathiamurthy M., Bui H., Wilson S. A roadmap for the immunomics of category A-C pathogens. Immunity 2005, 22:155-161.
47. Ingram R.J., Metan G., Maillere B., Doganay M., Ozkul Y., Kim L.U., et al. Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes. J Immunol 2010, 184(7):3814-3821.